Skip to main content
Top
Published in: Intensive Care Medicine 7/2014

01-07-2014 | Editorial

Amikacin dosing in the ICU: we now know more, but still not enough…

Authors: Francesco G. De Rosa, Jason A. Roberts

Published in: Intensive Care Medicine | Issue 7/2014

Login to get access

Excerpt

There are perfect studies and there are useful studies, such as the paper by de Montmollin et al. [1] in this issue of Intensive Care Medicine, which uses a simple study design to provide a strong and clinically relevant message that is very useful for daily work in the intensive care unit (ICU). Although a standard dosage of 15 mg/kg once daily is commonly used for amikacin, the authors evaluated the effect of a higher fixed weight-based amikacin dose in critically ill patients, 25 mg/kg, on achievement of concentration targets in a heterogeneous patient cohort. They found that even with a 25 mg/kg loading dose, 33 % of patients still did not achieve Cmax/MIC ratio [ratio of maximum concentration during dosing interval (Cmax) to the minimum inhibitory concentration of the known/suspected pathogen (MIC)] of 8–10, assuming the highest MIC of susceptible pathogens. …
Literature
1.
go back to reference de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M, Sonneville R (2014) Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med. doi:10.1007/s00134-014-3276-x de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M, Sonneville R (2014) Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med. doi:10.​1007/​s00134-014-3276-x
2.
go back to reference Roberts JA (2011) Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol 12:2070–2079PubMedCrossRef Roberts JA (2011) Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol 12:2070–2079PubMedCrossRef
3.
go back to reference Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051–1065PubMedCrossRef Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051–1065PubMedCrossRef
4.
go back to reference Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, Roberts MJ, Kruger P, Lipman J (2011) Antibiotic dosing in the ‘at risk’ critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 11:3PubMedCentralPubMedCrossRef Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, Roberts MJ, Kruger P, Lipman J (2011) Antibiotic dosing in the ‘at risk’ critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 11:3PubMedCentralPubMedCrossRef
5.
go back to reference Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Study D (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083PubMedCrossRef Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Study D (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083PubMedCrossRef
6.
go back to reference Roberts JA, Stove V, De Waele JJ, Sipinkoski B, McWhinney B, Ungerer JP, Akova M, Bassetti M, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, on behalf of the DALI Study authors (2014) Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. Int J Antimicrob Agents 43(5):423–430 Roberts JA, Stove V, De Waele JJ, Sipinkoski B, McWhinney B, Ungerer JP, Akova M, Bassetti M, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, on behalf of the DALI Study authors (2014) Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. Int J Antimicrob Agents 43(5):423–430
Metadata
Title
Amikacin dosing in the ICU: we now know more, but still not enough…
Authors
Francesco G. De Rosa
Jason A. Roberts
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 7/2014
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-014-3308-6

Other articles of this Issue 7/2014

Intensive Care Medicine 7/2014 Go to the issue